{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:29:56Z","timestamp":1765546196484},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,8,15]]},"abstract":"<jats:p> PURPOSE: We performed a prospective phase II study to assess the activity of thalidomide in patients with Waldenstrom\u2019s macroglobulinemia (WM). <\/jats:p><jats:p> PATIENTS AND METHODS: Twenty patients with WM were treated with thalidomide at a starting dose of 200 mg daily with dose escalation in 200-mg increments every 14 days as tolerated to a maximum of 600 mg. All patients were symptomatic, their median age was 74 years, and 10 patients were previously untreated. <\/jats:p><jats:p> RESULTS: On an intent-to-treat basis, five (25%) of 20 patients achieved a partial response after treatment. Responses occurred in three of 10 previously untreated and in two of 10 pretreated patients. None of the patients treated during refractory relapse or with disease duration exceeding 2 years responded to thalidomide. Time to response was short, ranging between 0.8 months to 2.8 months. Adverse effects were common but reversible and consisted primarily of constipation, somnolence, fatigue, and mood changes. The daily dose of thalidomide was escalated to 600 mg in only five patients (25%), and in seven patients (35%), this agent was discontinued within 2 months because of intolerance. <\/jats:p><jats:p> CONCLUSION: Our data indicate that thalidomide has activity in WM but only low doses were tolerated in this elderly patient population. Confirmatory studies as well as studies that will combine thalidomide with chemotherapy or with rituximab may be relevant. <\/jats:p>","DOI":"10.1200\/jco.2001.19.16.3596","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:33:42Z","timestamp":1487921622000},"page":"3596-3601","source":"Crossref","is-referenced-by-count":100,"title":["Treatment of Waldenstrom\u2019s Macroglobulinemia With Thalidomide"],"prefix":"10.1200","volume":"19","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[{"name":"From the Departments of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine; and Department of Hematology, Genimatas General Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanassios","family":"Zomas","sequence":"additional","affiliation":[{"name":"From the Departments of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine; and Department of Hematology, Genimatas General Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora A.","family":"Viniou","sequence":"additional","affiliation":[{"name":"From the Departments of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine; and Department of Hematology, Genimatas General Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Grigoraki","sequence":"additional","affiliation":[{"name":"From the Departments of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine; and Department of Hematology, Genimatas General Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Galani","sequence":"additional","affiliation":[{"name":"From the Departments of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine; and Department of Hematology, Genimatas General Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charis","family":"Matsouka","sequence":"additional","affiliation":[{"name":"From the Departments of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine; and Department of Hematology, Genimatas General Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Economou","sequence":"additional","affiliation":[{"name":"From the Departments of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine; and Department of Hematology, Genimatas General Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Anagnostopoulos","sequence":"additional","affiliation":[{"name":"From the Departments of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine; and Department of Hematology, Genimatas General Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayiotis","family":"Panayiotidis","sequence":"additional","affiliation":[{"name":"From the Departments of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine; and Department of Hematology, Genimatas General Hospital, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-093758","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)65225-2"},{"key":"R2-093758","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.6.1452.1452"},{"key":"R3-093758","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.214"},{"key":"R4-093758","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01918.x"},{"key":"R5-093758","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01461.x"},{"key":"R6-093758","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008350208019"},{"key":"R7-093758","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"R8-093758","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R9-093758","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2694"},{"key":"R10-093758","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01983.x"},{"key":"R11-093758","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200031"},{"key":"R12-093758","doi-asserted-by":"crossref","unstructured":"Alexanian  R,   Weber  D:   Thalidomide for resistant and relapsing myeloma.  Semin Hematol 37:  22,2000-25,     (suppl 1)","DOI":"10.1016\/S0037-1963(00)90079-9"},{"key":"R13-093758","doi-asserted-by":"publisher","DOI":"10.4065\/75.9.897"},{"key":"R14-093758","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.514"},{"key":"R15-093758","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2943"},{"key":"R16-093758","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412110"},{"key":"R17-093758","unstructured":"Neben  K,   Moehler  T,   Egerer  G,  et al:   High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.  Blood 96:  167a,2000  (abstr 721)"},{"key":"R18-093758","unstructured":"Weber  DM,   Rankin  K,   Gavino  M,  et al:   Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma.  Blood 96:  168a,2000  (abstr 724)"},{"key":"R19-093758","unstructured":"Rajkumar  SV,   Fonseca  R,   Dispenzieri  A,  et al:   A phase II trial of thalidomide in the treatment of relapsed multiple myeloma with laboratory correlative studies.  Blood 96:  168a,2000  (abstr 723)"},{"key":"R20-093758","unstructured":"Rajkumar  SV,   Timm  M,   Mesa  RA,  et al:   Effect of thalidomide on myeloma cell apoptosis and VEGF secretion.  Blood 96:  364a,2000  (abstr 1574)"},{"key":"R21-093758","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.754"},{"key":"R22-093758","doi-asserted-by":"publisher","DOI":"10.1053\/shem.2000.7389"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.16.3596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:45:10Z","timestamp":1653515110000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.16.3596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8,15]]},"references-count":22,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2001,8,15]]}},"alternative-id":["10.1200\/JCO.2001.19.16.3596"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.16.3596","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8,15]]}}}